Cancer Archives

Cancer immunotherapy resistance mechanism University Hospital Zurich

News and Trends 27 Jul 2017

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca imfinzi durvalumab tremelimumab

News and Trends 27 Jul 2017

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca’s MYSTIC study was evaluating a combination of checkpoint inhibitors as a first-line treatment for metastatic non-small cell lung cancer. The therapy couldn’t improve progression-free survival when compared with the standard of care […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jul 2017

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […]

July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

SHIVA Trial Precision Medicine Cancer France

In Depth 20 Jul 2017

SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer

SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field. Although molecular alterations are shared among different types of cancer, drug development today is still mainly based on tumor localization. The only recent exception is MSD’s Keytruda (pembrolizumab) an antibody approved by […]

July 20, 2017 - 5 minutesmins - By Timothé Cynober

Tiziana Life Sciences HCC milciclib cancer

News and Trends 19 Jul 2017

Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer

Update (19/07/2017): Tiziana has enrolled its first patient with refractory hepatocellular carcinoma in the Phase IIa trial with milciblib. Results are expected in the fourth quarter of 2018. Published on 24/04/2017 Tiziana Life Sciences has received approval to start Phase II in Israel with its leading compound, a CDK inhibitor targeting one of the deadliest cancers. […]

July 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 12 Jul 2017

Genomic Testing in Oncology: From Single Genes to Whole Genomes

Personalized medicine would be nothing without genomic testing tools. Here’s an overview of how the field has rapidly evolved in the past years. BRCA (BReast CAncer) is one of the most famous gene variants for breast cancer testing. But aside from being a game-changer from a scientific perspective, it also changed the laws of genomic testing. […]

July 12, 2017 - 5 minutesmins - By Timothé Cynober

News and Trends 11 Jul 2017

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Editor’s Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its thoughts on Novartis’ CAR-T candidate. Up front are serious safety concerns. Novartis’ CTL019, or Tisagenlecleucel, wowed the audience at ASH last fall with a stellar 82% […]

July 11, 2017 - 3 minutesmins - By Evelyn Warner

universal cancer vaccine mrna biontech personalized medicine

News and Trends 5 Jul 2017

Results are in from the First Human Trial of an Universal Cancer Vaccine

BioNTech has published results from the first clinical trial for an mRNA-based individualized vaccine with the potential to target all cancer types. Published in Nature, the results from the first trial in humans with a personalized mRNA cancer vaccine hint that BioNTech is on a promising track towards the development of a universal cancer vaccine. All […]

July 5, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Jul 2017

Cutting Through the BS in Biopharma: How To Spot Hype

Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […]

July 5, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 4 Jul 2017

British Liquid Biopsy for Ovarian Cancer Outperforms the Gold Standard

The British company Angle has announced results from a large-scale trial that seem to indicate its liquid biopsy technology could surpass the gold standard in ovarian cancer diagnosis. Angle, in the UK, is developing liquid biopsy tests to replace biopsies in the diagnosis of cancer. The company has announced results from a 400-patient trial in […]

July 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jun 2017

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […]

June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

Roche Abandons Spanish Cancer Epigenetics Drug

SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer

Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer

Genomic Testing in Oncology: From Single Genes to Whole Genomes

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Results are in from the First Human Trial of an Universal Cancer Vaccine

Cutting Through the BS in Biopharma: How To Spot Hype

British Liquid Biopsy for Ovarian Cancer Outperforms the Gold Standard

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!